BACKGROUND: Measured endocrinological parameters (total testosterone [TT], free testosterone [FT], dihydrotestosterone [DHT], dehydroepiandrosterone sulfate [DHEAS], and sex hormone binding globulin [SHBG]) and calculated parameters (calculated FT (cFT), calculated bioavailable testosterone (cBT), and the free androgen index [FAI]) in women with hirsutism were compared to the values of a control group. The question remains if cFT or cBT are more appropriate markers for assessment of hyperandrogenemia in clinical situations such as hirsutism in women. METHODS: Sixty-six women showed an modified Ferriman-Gallwey (mF-G) score of >or=6 and were classified as hirsutism group and 58 women showed mF-G scores of <or=5 and were classified as control group. TT, FT, DHT, DHEAS, and SHBG were measured with enzyme immunoassays in one serum sample. Albumin was measured in the same sample. Afterwards, cFT, cBT, and the FAI were calculated. RESULTS: The hirsutism group revealed significantly increased cFT, cBT, and FAI, while SHBG was significantly decreased compared to the controls. All values of the hirsutism group showed significant, but poor correlation with the mF-G score. SHBG correlated negatively with the mF-G score and BMI. CONCLUSION: Despite the limited correlation of all endocrinological parameters to severity of hirsutism described by the mF-G score, cFT, cBT, and FAI may be more appropriate markers for assessment of hyperandrogenemia in women with hirsutism in comparison with measured values of simple enzyme immunoassays. Copyright (c) 2007 S. Karger AG, Basel.
BACKGROUND: Measured endocrinological parameters (total testosterone [TT], free testosterone [FT], dihydrotestosterone [DHT], dehydroepiandrosterone sulfate [DHEAS], and sex hormone binding globulin [SHBG]) and calculated parameters (calculated FT (cFT), calculated bioavailable testosterone (cBT), and the free androgen index [FAI]) in women with hirsutism were compared to the values of a control group. The question remains if cFT or cBT are more appropriate markers for assessment of hyperandrogenemia in clinical situations such as hirsutism in women. METHODS: Sixty-six women showed an modified Ferriman-Gallwey (mF-G) score of >or=6 and were classified as hirsutism group and 58 women showed mF-G scores of <or=5 and were classified as control group. TT, FT, DHT, DHEAS, and SHBG were measured with enzyme immunoassays in one serum sample. Albumin was measured in the same sample. Afterwards, cFT, cBT, and the FAI were calculated. RESULTS: The hirsutism group revealed significantly increased cFT, cBT, and FAI, while SHBG was significantly decreased compared to the controls. All values of the hirsutism group showed significant, but poor correlation with the mF-G score. SHBG correlated negatively with the mF-G score and BMI. CONCLUSION: Despite the limited correlation of all endocrinological parameters to severity of hirsutism described by the mF-G score, cFT, cBT, and FAI may be more appropriate markers for assessment of hyperandrogenemia in women with hirsutism in comparison with measured values of simple enzyme immunoassays. Copyright (c) 2007 S. Karger AG, Basel.
Authors: Lauren W Roth; Hao Huang; Richard S Legro; Michael P Diamond; Christos Coutifaris; Sandra A Carson; Michael P Steinkampf; Bruce R Carr; Peter G McGovern; Nicholas A Cataldo; Gabriella G Gosman; John E Nestler; Evan R Myers; Heping Zhang; William D Schlaff Journal: Obstet Gynecol Date: 2012-06 Impact factor: 7.661
Authors: Richard S Legro; William D Schlaff; Michael P Diamond; Christos Coutifaris; Peter R Casson; Robert G Brzyski; Gregory M Christman; J C Trussell; Stephen A Krawetz; Peter J Snyder; Dana Ohl; Sandra A Carson; Michael P Steinkampf; Bruce R Carr; Peter G McGovern; Nicholas A Cataldo; Gabriella G Gosman; John E Nestler; Evan R Myers; Nanette Santoro; Esther Eisenberg; Meizhuo Zhang; Heping Zhang Journal: J Clin Endocrinol Metab Date: 2010-09-08 Impact factor: 5.958
Authors: P Falcetta; E Benelli; A Molinaro; C Di Cosmo; B Bagattini; S Del Ghianda; G Salvetti; E Fiore; E Pucci; F Fruzzetti; M Tonacchera Journal: J Endocrinol Invest Date: 2021-06-05 Impact factor: 4.256